SOHO 2021 | The mutagenic impact of melphalan in myeloma
Ola Landgren
• 23 Aug 2021
Ola Landgren, MD, PhD, of Sylvester Comprehensive Cancer Center, University of Miami, FL, talks on the mutagenic impact of melphalan, a treatment for patients with multiple myeloma. Dr Landgren outlines the history of melphalan use in patients with myeloma and describes how high doses of melphalan have been shown to directly impact the mutational signature SBS-MM1, resulting in an increased mutational burden detected between diagnosis and relapse. In todays treatment landscape, Dr Landgren questions whether melphalan needs to be added to treatment regimens. This interview took place during the ninth annual meeting of the Society of Hematologic Oncology (SOHO 2021) congress.
